Targeted antibodies have been developed against the checkpoint protein programmed death receptor 1 (PD1). The goal of therapy is to inhibt PD1.
anti-PD-1 antibodies include: pembrolizumab, nivolumab, lambrolizumab
Common adverse effects:
(1) fever and chills
(2) lethargy
(3) maculopapular rash
(4) hypophysitis
(5) thyroiditis
(6) adrenal insufficiency
The rash appears early and endocrinopathies later.
Uncommon side effects:
(1) enterocolitis with diarrhea
(2) elevated liver function tests
(3) pneumonitis
(4) neuropathy
(5) Guillain-Barre syndrome
(6) mysasthenia gravis
(7) nephritis
To read more or access our algorithms and calculators, please log in or register.
Specialty: Hematology Oncology, Immunology/Rheumatology
ICD-10: ,
